Kenya Pharmaceuticals & Healthcare Report Q4 2014 - New Market Research Report

Investment into Kenya's healthcare sector by pharmaceutical and medical device companies is an advisable business strategy - as highlighted by the high growth forecast in healthcare spending between 2013 and 2018. However, we note that there are downside risks to our forecast , including government inefficiencies and the out-of-pocket characteristics of the market , which will act as challenges for companies looking for a rapid return on investment.

Headline Expenditure Projections

* Pharmaceuticals: KES55.29bn (USD642mn) in 2013 to KES64.32bn (USD742mn) in 2014; 16.3% growth in local currency terms and 15.6% in US dollar terms.
* Healthcare: KES184.27bn (USD2.14bn) in 2013 to KES207.59bn (USD2.40bn) in 2014; 12.7% growth in local currency terms and 12.0% in US dollar terms.

Risk/Reward Rating

In BMI's Q414 Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), Kenya is 19th in the Middle East and Africa (MEA). A large counterfeiting industry, poor healthcare funding, corruption, regulatory deficiencies and a number of other issues will conspire to keep Kenya in a low position in the MEA matrix. Nevertheless, in comparison with many other African markets, most of which are not surveyed by BMI, Kenya offers more commercial promise and a more stable overall business environment.

Full Report Details at
- http://www.fastmr.com/prod/861864_kenya_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=303

Key Trends And Developments

On June 12 2014, Treasury Cabinet Secretary Henry Rotich presented Kenya's KES1.8trn (USD20.57bn) budget for the 2014/2015 fiscal year, which will begin on July 1 2014. For healthcare, a total of KES47.4bn (USD541mn) has been allocated to the sector, focused on enhancing the quality and accessibility of healthcare services in the country.

In July 2014, Kenya's Reproductive Health Care Bill received mixed reactions, with some in support of the bill, claiming that it will lower the HIV infection rate and help address the increasing incidence of teenage pregnancy. Meanwhile others have criticised it, stating that it will affect children's...

The Kenya Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kenya Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kenyan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kenya to test other views - a key input for successful budgeting and strategic business planning in the Kenyan pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Mexico Pharmaceuticals & Healthcare Report Q4 2014
- Thailand Pharmaceuticals & Healthcare Report Q4 2014
- Australia Pharmaceuticals & Healthcare Report Q4 2014
- Croatia Pharmaceuticals & Healthcare Report Q4 2014